Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Jaguar Health (JAGX) over the last 11 years, with Q3 2025 value amounting to $2.5 million.

  • Jaguar Health's Other Operating Expenses fell 86.24% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 3167.11%. This contributed to the annual value of $9.6 million for FY2024, which is 878.44% up from last year.
  • Latest data reveals that Jaguar Health reported Other Operating Expenses of $2.5 million as of Q3 2025, which was down 86.24% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Jaguar Health's Other Operating Expenses peaked at $4.2 million during Q1 2021, and registered a low of $1.9 million during Q1 2024.
  • Moreover, its 5-year median value for Other Operating Expenses was $2.6 million (2022), whereas its average is $2.7 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first tumbled by 5312.06% in 2021, then surged by 6059.8% in 2025.
  • Jaguar Health's Other Operating Expenses (Quarter) stood at $2.8 million in 2021, then fell by 18.94% to $2.2 million in 2022, then grew by 15.43% to $2.6 million in 2023, then grew by 26.38% to $3.3 million in 2024, then dropped by 22.71% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $3.0 million for Q2 2025, and $3.0 million during Q1 2025.